

## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn20>

### SYNTHESIS OF SOME 2'- AND 3'-FLUOROALKYL SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDES

Pawel J. Serafinowski<sup>a</sup>, Catherine A. Brown<sup>a</sup> & Colin L. Barnes<sup>a</sup>

<sup>a</sup> CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, United Kingdom

Published online: 07 Feb 2007.

To cite this article: Pawel J. Serafinowski, Catherine A. Brown & Colin L. Barnes (2001) SYNTHESIS OF SOME 2'- AND 3'-FLUOROALKYL SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDES, *Nucleosides, Nucleotides and Nucleic Acids*, 20:4-7, 921-925, DOI: [10.1081/NCN-100002459](https://doi.org/10.1081/NCN-100002459)

To link to this article: <http://dx.doi.org/10.1081/NCN-100002459>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

## SYNTHESIS OF SOME 2'- AND 3'-FLUOROALKYL SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDES

Pawel J. Serafinowski,\* Catherine A. Brown, and Colin L. Barnes

CRC Centre for Cancer Therapeutics, Institute of Cancer Research,  
Sutton, Surrey SM2 5NG, United Kingdom

As part of a programme on the development of antisense oligonucleotides, as selective inhibitors of oncogene expression, it was intended to investigate the properties of oligonucleotides modified at the 2'- or 3'-position with difluoromethylene, difluoromethyl and trifluoromethyl groups. It was expected that such oligonucleotides might possess increased stability against nucleases as well as improved hybridisation properties and transport characteristics (1,2,3).


The synthesis of target oligonucleotides entailed prior preparation of the appropriate nucleoside precursors. It was found that reaction of suitably protected 2'- and 3'-ketonucleosides with crystalline bromodifluoromethyl[tris (dimethylamino)]-phosphonium bromide in the presence of zinc gave 2'- and 3'-difluoromethylene nucleosides in high yields (4-6). Subsequently, these compounds were used as starting materials for further transformations.

Thus, hydrogenation of 2'-deoxy-2'-difluoromethylene-5'-*O*-dimethoxytrityluridine (**1**) (4) and 3'-deoxy-3'-difluoromethylene-5'-*O*-dimethoxytrityluridine (**4**) (4), gave the corresponding 2'- and 3'-difluoromethyluridine derivatives **2a/2b** (*threo/erythro* 6:1) and **5a/5b** (*threo/erythro* 8:1), respectively. Detritylation of compounds **2a/2b** and **5a/5b** provided two pairs of diastereoisomers, **3a/3b** (7) and **6a/6b** (7), that could be separated by HPLC.

Interestingly, reaction of 2'-deoxy-2'-difluoromethylene-5'-*O*-dimethoxytrityl-3'-*O*-trimethylsilylethoxymethyluridine (**11**) (6) and 3'-deoxy-3'-difluoromethylene-5'-*O*-dimethoxytrityl-2'-*O*-trimethylsilylethoxymethyluridine (**17**) (6) with tetrabutylammonium fluoride, resulted in fluorination at the unsaturated difluoromethylene carbon with loss of the trimethylsilylethoxymethyl


group and formation of 2',3'-dideoxy-2',3'-dideoxy-5'-*O*-dimethoxytrityl-2'-trifluoromethyluridine (**13**) and 2',3'-dideoxy-2',3'-dideoxy-5'-*O*-dimethoxytrityl-3'-trifluoromethyluridine **19**, respectively.

No products of expected desilylation such as **12** and **18** were detected. Detritylation of **13** and **19** afforded the expected 2',3'-dideoxy-2',3'-dideoxy-2' (3')-trifluoromethyluridines **14** and **20**. Hydrogenation of compounds **13** and **19** followed by detritylation provided 2',3'-dideoxy-2'-trifluoromethyluridine (**16a**) and



**Scheme 1.** Synthesis of 3'- and 2'-*O*-Phosphoramidites of 2'- and 3'-Difluoromethylneuridine and 2'- and 3'-Difluoromethyluridine.





**Scheme 2.** Synthesis of 2'- and 3'-trifluoromethyluridine derivatives.

2',3'-dideoxy-3'-trifluoromethyluridine (**22a**), along with the corresponding threo isomers **16b** and **22b**, respectively (6). (Scheme 2).

Finally, phosphorylation of compounds **1**, **2a**, **4** and **5a** furnished the corresponding 2'- and 3'-O-phosphoramidites (**7**) (**4**), (**8**) (**7**), (**9**) (**4**) and (**10**) (**7**). (Scheme 1) Attempted incorporation of 3'-deoxy-3'-difluoromethylene-5'-O-dimethoxytrityluridine-2'-O-phosphoramidite (**9**) into oligonucleotide sequences was only possible after detailed studies in solution to customise the standard solid phase protocol. Replacement of iodine with t-butylhydroperoxide and the succinyl linker with oxalyl linker enabled the synthesis of short alternating oligonucleotides (8).

The incorporation of 2'-deoxy-2'-difluoromethyl-5'-O-dimethoxytrityluridine-2'-O-phosphoramidite (**8**), and its 3'-difluoromethyl counterpart **10**, required



fewer changes in the standard protocol and resulted in (2'-5') and (3'-5') linked oligonucleotides modified with 3'- or 2'-difluoromethyl groups.

## ACKNOWLEDGMENTS

These investigations were supported by the Cancer Research Campaign.

## REFERENCES

1. Cook, P.D. *Annual Reports in Medicinal Chemistry* **1999**, 33, 313-325.
2. Schmit, C.; Béviere, M.O.; De Mesmaeker, A.; Altman, K.H. *Bioorg. & Med. Chem. Lett.* **1994**, 4, 1969-1976.
3. Schmit, C. *Synlett.* **1994**, 241-242.
4. Serafinowski, P.J.; Barnes, C.L. *Tetrahedron.* **1996**, 52 (23), 7929-7938.
5. Serafinowski, P.J.; Barnes, C.L. *Synthesis.* **1997**, 225-228.
6. Serafinowski, P.J.; Brown, C.A. *Tetrahedron.* **2000**, 56 (4), 333-339.
7. All the NMR spectra were recorded in DMSO-d<sub>6</sub> and UV spectra in 95% EtOH. **3a** NMR  $\delta_{\text{H}}$  3.02 (m, 1H, H-2'), 3.63 (m, 3H, H-4', H-5', H-5''), 4.33 (t, 1H, H-3' J = 7.69 Hz), 4.95 (bs, 1H, 5' -OH), 5.61 (d, 1H, H-6, J = 8.12 Hz), 5.83 (d, 1H, 3' -OH, J = 7.25 Hz), 6.02 (t of d, 1H, CF<sub>2</sub>H, J<sub>HF</sub> = 45.6 Hz, J<sub>HH</sub> = 4.47 Hz), 6.21 (d, 1H, H-1', J = 7.75 Hz), 7.84 (d, 1H, H-6, J = 8.12 Hz), 11.41 (bs, 1H, NH);  $\delta_{\text{C}}$  51.60 (t, J<sub>C-F</sub> = 19 Hz, C-2'), 57.96 (C-5'), 66.31 (C-3'), 81.04 (C-1'), 83.84 (C-4'), 100.44 (C-5), 114.54 (t, J<sub>C-F</sub> = 240 Hz, CF<sub>2</sub>H), 140.18 (C-6), 149.31 (C-2), 162.13 (C-4);  $\delta_{\text{F}}$  -117.17 (1F, d (J<sub>FF</sub> = 292 Hz) of d (J<sub>Hgem-F</sub> = 54.6 Hz), -121.46 (1F, d (J<sub>FF</sub> = 292 Hz) of d (J<sub>Hgem-F</sub> = 53.53 Hz); UV  $\lambda_{\text{max}}$  259 nm  $\epsilon_{\text{max}}$  6468,  $\lambda_{\text{min}}$  229 nm  $\epsilon_{\text{min}}$  1564; Observed FAB MS 279.0770, [C<sub>10</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub> + H]<sup>+</sup> requires 279.0793. **3b** NMR  $\delta_{\text{H}}$  2.89 (m, 1H, H-2'), 3.59 (m, 2H, H-5', H-5''), 3.85 (m, 1H, H-4'), 4.36 (d, 1H, -3', J = 4.48 Hz), 5.12 (bs, 1H, 5' -OH), 5.69 (d, 1H, H-5, J = 8.13 Hz), 5.79 (bs, 1H, 3' -OH), 6.33 (d, 1H, H-1', J = 8.53 Hz), 6.19 (t of d, 1H, CF<sub>2</sub>H, J<sub>HF</sub> = 55.4 Hz, J<sub>HH</sub> = 6.80 Hz), 7.85 (d, 1H, H-6, J = 8.13 Hz), 11.32 (bs, 1H, NH);  $\delta_{\text{F}}$  -114.58 (1F, d (J<sub>FF</sub> = 295 Hz) of q (J<sub>Hgem-F</sub> = 54.1 Hz, J<sub>H2'-F</sub> = 10.0 Hz), -123.51 (1F, d (J<sub>FF</sub> = 295 Hz) of q (J<sub>Hgem-F</sub> = 55.9 Hz, J<sub>H2'-F</sub> = 14.3 Hz); UV  $\lambda_{\text{max}}$  260 nm  $\epsilon_{\text{max}}$  7426,  $\lambda_{\text{min}}$  230 nm  $\epsilon_{\text{min}}$  1098; Observed FAB MS 279.0702, [C<sub>10</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub> + H]<sup>+</sup> requires 279.0793. **6a** NMR  $\delta_{\text{H}}$  2.87 (m, 1H, H-3'), 3.57 (m, 2H, H-5', H-5''), 4.30 (m, 2H, H-2', H-4'), 5.32 (bs, 1H, 5' -OH), 5.71 (m, 3H, H-1', 2' -OH, H-5), 6.31 (t of d, 1H, CF<sub>2</sub>H, J<sub>HF</sub> = 49.08 Hz, J<sub>HH</sub> = 6.88 Hz), 7.84 (d, 1H, H-6, J = 8.16 Hz), 11.34 (bs, 1H, NH);  $\delta_{\text{C}}$  C-2'), 49.38 (t, J<sub>C-F</sub> = 19.5 Hz, C-3'), 60.58 (C-5'), 76.90 (C-4'), 87.96 (C-1'), 102.40 (C-5), 116.96 (t, J<sub>C-F</sub> = 251 Hz, CF<sub>2</sub>H), 140.69 (C-6), 150.92 (C-2), 163.03 (C-4);  $\delta_{\text{F}}$  -112.08 (1F, d (J<sub>FF</sub> = 294 Hz) of q (J<sub>Hgem-F</sub> = 55.55 Hz, J<sub>H-3'-F</sub> = 11.57 Hz), -116.75 (1F, d (J<sub>FF</sub> = 294 Hz) of q (J<sub>Hgem-F</sub> = 56.3 Hz, J<sub>H-3'-F</sub> = 15.08 Hz); UV  $\lambda_{\text{max}}$  260 nm  $\epsilon_{\text{min}}$  8778  $\lambda_{\text{min}}$  229 nm  $\epsilon_{\text{min}}$  3436; Observed ES MS 279.0802, [C<sub>10</sub>H<sub>12</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub> + H]<sup>+</sup> requires 279.0793. **6b** NMR  $\delta_{\text{H}}$  2.73 (m, 1H, H-3'), 3.52 (m, 1H, H-5'), 3.75 (m, 1H, H-5''), 4.34 (m, 3H, H-2', H-4', 5' -OH), 5.61 (d, 1H, J = 8.24 Hz, H-5), 5.68 (bs, 2H, 3' -OH, H-1'), 6.20 (t, J<sub>HF</sub> = 56.1 Hz of d J<sub>HH</sub> = 5.28 Hz, 1H, CF<sub>2</sub>H), 7.98 (d, 1H, H-6, J = 8.24 Hz), 11.30 (bs, 1H, NH);  $\delta_{\text{F}}$  -116.03 (1F, d (J<sub>FF</sub> = 290 Hz) of q (J<sub>Hgem-F</sub> =



55.6 Hz,  $J_{\text{H3-F}} = 10.06$  Hz) ,  $-122.70$  1F d ( $J_{\text{FF}} = 290$  Hz) of q ( $J_{\text{Hgem-F}} = 57.1$  Hz,  $J_{\text{H3'-F}} = 18.7$  Hz); UV  $\lambda_{\text{max}}$  262 nm  $\epsilon_{\text{max}}$  8885  $\epsilon_{\text{min}}$  230 nm  $\epsilon_{\text{min}}$  2020; Observed FAB MS 301.0600,  $[\text{C}_{10}\text{H}_{12}\text{F}_2\text{N}_2\text{O}_5 + \text{Na}]^+$  requires 301.0612. **3a** - 2D NOESY showed a cross peak between H-2' and H-4' and at the same time the lack of a cross peak between H-2' and H-5'. There was also a cross peak between H-6 and  $\text{CF}_2\text{H}$ . This is only possible if the H-2' proton is on the  $\alpha$  face. **3b** - 2D NOESY showed a cross peak between H-2' and H-5 and at the same time the lack of a cross peak between H-2' and H-4'. This is only possible if the H-2' proton is on the  $\beta$  face. **6a** - 2D NOESY showed a cross peak between between H-5' and  $\text{CF}_2\text{H}$ . and at the same time the lack of a cross peak between H-3' and H-5'. There was also a cross peak between H-6 and  $\text{CF}_2\text{H}$ . This is only possible if the H-3' proton is on the  $\alpha$  face. **6b** - 2D NOESY showed a cross peak between H-4' and  $\text{CF}_2\text{H}$  and at the same time the lack of a cross peak between H-5' and  $\text{CF}_2\text{H}$ . There was also a cross peak between H-3' and H-6. This is only possible if the H-3' proton is on the  $\beta$  face.

8. NMR  $\delta_{\text{H}}$  1.05–1.14H (m, 14H, iPr), 2.59 (m, 1H, H-2'), 2.72 (t, 2H,  $J = 5.50$  Hz,  $\text{OCH}_2\text{CH}_2\text{CN}$ ), 3.45 (m, 2H, iPr), 3.51 (m, 2H, H-5', H-5''), 3.73 (s, 6H,  $\text{OCH}_3$ ), 4.04 (m, 3H,  $\text{OCH}_2\text{CH}_2\text{CN}$ , H-4'), 4.67 (m, 1H, H-3'), 5.31 (d, 1H, H-5,  $J = 9.13$  Hz), 6.10 t ( $J_{\text{HF}} = 56$  Hz) of m, 1H,  $\text{CF}_2\text{H}$ ), 6.30(m, 1H, H-1'), 6.87–7.42 (m, 13H, trityl), 7.65 ( 2 d, unresolved, H-6), 11.39 (bs, 1H, NH);  $\delta_{\text{F-}}$  117.9 (d of m, 1F,  $\text{CF}_2\text{H}$  ),  $-122.2$  (d of m, 1F,  $\text{CF}_2\text{H}$  )  $\delta_{\text{P}}$  150.18 (s), 150.64 (s); Observed FAB MS 779.3050,  $[\text{C}_{40}\text{H}_{47}\text{F}_2\text{N}_4\text{O}_8\text{P-H}]$  requires 779.3021. **10** NMR  $\delta_{\text{H}}$ , (1.21 , m, 14H, iPr), 2.88 (t, 2H,  $J = 6.82$  Hz,  $\text{OCH}_2\text{CH}_2\text{CN}$ ), 2.99 (m, 1H, H-3'), 3.48(m, 4H, H-5', H-5'', iPr), 3. 71 (s, 6H,  $\text{OCH}_3$ ), 4.04 (m, 3H,  $\text{OCH}_2\text{CH}_2\text{CN}$ , H-4'), 4.51 (m, 1H, H-2'), 5.59 (d, 1H, H-5,  $J = 8.11$  Hz), 5.89 (d, 1H, H-1',  $J = 5.62$  Hz), 6.18 t ( $J_{\text{HF}} = 48.5$  Hz) of m, 1H,  $\text{CF}_2\text{H}$ ), 6.82–7.45 (m, 13H, trityl), 7.55 (d, 1H, H-6,  $J = 8.11$  Hz), 11.34 (s, 1H, NH);  $\delta_{\text{F-}}$   $-112.58$ –( $-114.86$ ) (m, 1F,  $\text{CF}_2\text{H}$ )  $-117.11$ –( $-118.99$ ) (m, 1F,  $\text{CF}_2\text{H}$ );  $\delta_{\text{P}}$  152.502 (s), 152.409 (s) ; Observed FAB MS 779.3063,  $[\text{C}_{40}\text{H}_{47}\text{F}_2\text{N}_4\text{O}_8\text{P-H}]$  requires 779.3021.

8. Brown, C.A.; Barnes, C.L.; Serafinowski, P.J. *Nucleosides & Nucleotides*, **1999**, *18* (6&7), 1249–1250.



## **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

**[Order now!](#)**

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002459>